Publicaciones en las que colabora con Oscar Briz Sánchez (49)

2024

  1. Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide

    Biomedicine and Pharmacotherapy, Vol. 170

2023

  1. Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs

    Biomedicine and Pharmacotherapy, Vol. 168

  2. Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells

    Biomedicine and Pharmacotherapy, Vol. 165

2022

  1. Expression of Chemoresistance-Associated ABC Proteins in Hepatobiliary, Pancreatic and Gastrointestinal Cancers

    Cancers, Vol. 14, Núm. 14

  2. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems

    Seminars in Liver Disease, Vol. 42, Núm. 1, pp. 087-103

2020

  1. Cellular mechanisms accounting for the refractoriness of colorectal carcinoma to pharmacological treatment

    Cancers, Vol. 12, Núm. 9, pp. 1-34

  2. Molecular bases of drug resistance in hepatocellular carcinoma

    Cancers, Vol. 12, Núm. 6, pp. 1-26

  3. Molecular bases of mechanisms accounting for drug resistance in gastric adenocarcinoma

    Cancers, Vol. 12, Núm. 8, pp. 1-29

  4. Role of genetic variations in the hepatic handling of drugs

    International Journal of Molecular Sciences, Vol. 21, Núm. 8

2019

  1. Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib

    British Journal of Pharmacology, Vol. 176, Núm. 6, pp. 787-800

  2. Unraveling ‘The Cancer Genome Atlas’ information on the role of SLC transporters in anticancer drug uptake

    Expert Review of Clinical Pharmacology, Vol. 12, Núm. 4, pp. 329-341

  3. What “The Cancer Genome Atlas” database tells us about the role of ATP-binding cassette (ABC) proteins in chemoresistance to anticancer drugs

    Expert Opinion on Drug Metabolism and Toxicology, Vol. 15, Núm. 7, pp. 577-593

2018

  1. Chemoresistance and chemosensitization in cholangiocarcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1444-1453

  2. Genetic heterogeneity of SLC22 family of transporters in drug disposition

    Journal of Personalized Medicine, Vol. 8, Núm. 2

  3. Interaction of glucocorticoids with FXR/FGF19/FGF21-mediated ileum-liver crosstalk

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 9, pp. 2927-2937

  4. Molecular bases of the poor response of liver cancer to chemotherapy

    Clinics and Research in Hepatology and Gastroenterology

  5. Role of drug transporters in the sensitivity of acute myeloid leukemia to sorafenib

    Oncotarget, Vol. 9, Núm. 47, pp. 28474-28485

2017

  1. Molecular bases of chemoresistance in cholangiocarcinoma

    Current Drug Targets, Vol. 18, Núm. 8, pp. 889-900

2016

  1. Protective role of biliverdin against bile acid-induced oxidative stress in liver cells

    Free Radical Biology and Medicine, Vol. 97, pp. 466-477

2015

  1. Enhanced antitumour drug delivery to cholangiocarcinoma through the apical sodium-dependent bile acid transporter (ASBT)

    Journal of Controlled Release, Vol. 216, pp. 93-102